Current therapies for hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is the most common inherited heart diseases. Yet, there is currently no specific course of management or treatment for patients suffering with hypertrophic cardiomyopathy which modifies disease expression. This review synthesised current therapies, finding that invasive septal reductions increase VO2max, improve symptoms and reduce both resting and peak left ventricular outflow tract gradient. Pharmacological interventions were found to improve reported NYHA class, but these drugs often have limited effects. New cardioselective drugs provide hope for patients suffering with hypertrophic cardiomyopathy, as they present effects similar to that of invasive procedures. Exercise programs were also found to improve functional capacity.
This review by Bayonas-Ruiz A et al. aimed to aimed to discuss current therapies for hypertrophic cardiomyopathy and their effects, as well as future potential treatments.
Further research is required into the best treatments for hypertrophic cardiomyopathy, including further insight into the potential of cardioselective drugs. Personalised management plans involving different approaches, which may include invasive treatments, exercise regimes and therapeutic agents, may be helpful for the management of patients with hypertrophic cardiomyopathy.